Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2018

Supporting Information

Stereoselective allylic reduction via one-pot palladium-catalyzed allylic sulfonation and sulfinyl retro-ene reactions

Hyun-Suk Um, Jungki Min, Taeyang An, Jin Choi and Chulbom Lee*

Department of Chemistry, Seoul National University, Seoul 08826, Republic of Korea chulbom@snu.ac.kr

I. General Information

All solvents were obtained by passing through activated alumina columns of solvent purification systems from Glass Contour. Commercially available reagents were obtained from Sigma-Aldrich, Alfa Aesar, Strem, Acros or TCI and used without further purification.

NMR spectra were obtained on an Agilent 400-MR DD2 Magnetic Resonance System (400 MHz) and a Varian/Oxford As-500 (500 MHz) spectrophotometer. Chemical shift values were recorded as parts per million relative to tetramethylsilane as an internal standard unless otherwise indicated, and coupling constants in Hertz. The following abbreviations (or combinations thereof) were used to explain the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad. IR spectra were measured on a Thermo Scientific Nicolet 6700 spectrometer. High resolution mass spectra were recorded from the Organic Chemistry Research Center at Sogang University (Seoul) on a Brucker Compact or ThermoFisher Scientific using electrospray ionization (ESI) method. Specific rotations were obtained on a JASCO P-1030 polarimeter. Chiral HPLC spectra were obtained on a HPLC Hewlett Packard 1100 Series.

The progress of reaction was checked on thin layer chromatography (TLC) plates (Merck 5554 Kiesel gel 60 F254), and the spots were visualized under 254 nm UV and/or charring after dipping the TLC plate into a vanillin solution (15.0 g of vanillin and 2.5 mL of concentrated sulfuric acid in 250 mL of ethanol), a KMnO₄ solution (3.0 g of potassium permanganate, 20.0 g of potassium carbonate, and 5.0 mL of 5% sodium hydroxide solution in 300 mL of water), or a ceric ammonium sulfate (CAM) solution (5 g of cerium sulfate, 25 g of ammonium molybdate tetrahydrate, 50 mL of concentrated sulfuric acid in 450 mL of water). Column chromatography was performed on silica gel (Merck 9385 Kiesel gel 60) using an appropriate eluent system.

II. Preparation of Sulfinate (TBSOMS-Na) from RongaliteTM

To an argon-purged flask were added 80 mmol of TBSCl (4.0 equiv) and 20 mmol of RongaliteTM (1.0 equiv) and the solid mixture was gently stirred and cooled to 0 °C with an ice-water bath. Pyridine (1 M with respect to RongaliteTM) was added to the flask over a few minutes. The resulting mixture was stirred for 12 h at room temperature under inert atmosphere. Pyridine was removed *in vacuo* and pyridinium salt was filterated through Celite with hexanes. The filterate was concentrated *in vacuo*, and a solution of the corresponding filterate in DCM (60 mL) was prepared under inert atmosphere at 0 °C. To the solution was dropwise added 19 mmol of sodium methoxide (1.0 M or 5.4 M in MeOH; 0.95 equiv). The reaction mixture was vigorously stirred at room temperature until the solution turned into a heterogeneous white solution. Solvent was removed under reduced pressure and the white precipitate was gathered, washed several times with hexanes and dried for a day under vacuum (or under a stream of nitrogen) to provide the corresponding sulfinate salt (54%).

III. General Procedure for the Preparation of Substrates

To a solution of allylic alcohol (1.0 equiv) in THF (0.5 M), which was prepared in a way reported in the corresponding literature, were added base (pyridine or "BuLi; 1.1 equiv) and a corresponding reagent (acetyl chloride for the preparation of acetate, methyl chloroformate for the preparation of methyl carbonate and Boc anhydride for the preparation of *tert*-butyldimethyl carbonate; 1.1 equiv) at -78 °C or 0 °C. Reaction mixture was stirred at room temperature. After full conversion of allylic alcohol, which was observed by TLC monitoring, reaction was quenched with *sat. aq.* NH₄Cl solution. Organic fractions were extracted by dichloromethane or ethyl acetate, washed with H₂O and brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography with an appropriate eluent system to give corresponding allylic acetate or carbonate.

IV. General Procedure for the Tandem S-Allylation-Rearrangement Reaction

To an argon-purged flask with a stir bar were added 0.275 mmol of sulfinate (1.1 equiv) and 0.4 mL of H₂O. The aqueous solution was degassed by argon bubbling for 30 minutes. To another argon-purged flask were added 0.25 mmol of allylic carbonate (1.0 equiv), 0.0375 mmol of PPh₃ (0.15 equiv), 0.00625 mmol of $[(\eta^3 -$

allyl)PdCl]₂ and 1.6 mL of THF. The organic solution in THF was transferred into the aqueous solution by cannulation, and the reaction mixture was stirred at room temperature for 12 h under inert atmosphere. 0.75 mmol of TFA (3.0 equiv.) was then directly added to the solution and the reaction mixture was kept stirring at 70 °C for additional 12 h. After the reaction mixture was cooled to room temperature, the mixture was filtered through Celite. The filterate was washed with *sat. aq.* NaHCO₃ solution, H₂O and brine, dried over Na₂SO₄ and concentrated. The residue was purified by flash column chromatography with an appropriate eluent system to give corresponding alkene.

V. Screening Experiments for the Optimization of Reaction Conditions



Table S1. Primary screening of palladium catalyzed S-allylation

catalyst ^[a]	additive ^[b]	solvent ^[c]	results ^[d]
Pd(PPh ₃) ₄	-	DCM-H ₂ O (4:1)	No Reaction
Pd(PPh ₃) ₄	TBAB	DCM-H ₂ O (4:1)	No Reaction
Pd(PPh ₃) ₄	TBAB	DCM-MeOH (4:1)	No Reaction
Pd ₂ (dba) ₃	TBAB	DCM-H ₂ O (4:1)	No Reaction
Pd(dba) ₂	TBAB	DCM-H ₂ O (4:1)	No Reaction
[(C ₃ H ₅)PdCl] ₂ / PPh ₃	TBAB	DCM-H ₂ O (4:1)	74%

^[a] 10 mol% of palladium catalyst (with 30 mol% of phosphine ligand, if necessary)

^[b] 1.0 equiv

^[c] 2.0 mL of total volume

^[d] isolated yield



Table S2. Leaving group screening of palladium catalyzed S-allylation

^[a] isolated yield

Table S3. Solvent screening of palladium catalyzed S-allylation



^[a] isolated yield

Table S4. Equivalent screening of palladium catalyzed S-allylation

BnO + 0.15 mmol	$\begin{array}{c} O \\ H \\ NaO^{-} S \\ TBSOMS-Na \end{array} \qquad \begin{array}{c} [(C_3H_5)P \\ \hline T \\ THF-H_2 \\ \end{array}$	dCl] ₂ / PPh ₃ BAB ₂ O (4:1), rt	O, O Ś OTBS
$[(C_3H_5)PdCl]_2 / PPh_3$	TBSOMS-Na	ТВАВ	results ^[a]
5 mol% / 30 mol%	1.5 equiv	1.0 equiv	98%
5 mol% / 30 mol%	1.5 equiv	-	84%
2.5 mol% / 15 mol%	1.5 equiv	-	79%
1.25 mol% / 7.5 mol%	1.5 equiv	-	71%
2.5 mol% / 15 mol%	1.1 equiv	-	90%
2.5 mol% / 15 mol%	1.1 equiv	-	97% ^[b]

^[a] isolated yield

^[b] 0.25 mmol instead of 0.15 mmol

Table S5. Screening of allylic sulfinic acid rearrangement



acid^[a] temperature

HCI / MeOH	50 °C	DCM-H ₂ O (4:1)	-
HCI / MeOH	50 °C	DCE	40%
HCI / MeOH	50 °C	THF-H ₂ O (4:1)	70%
AcOH	50 °C	THF-H ₂ O (4:1)	50%
AcOH	70 °C	THF-H ₂ O (4:1)	71%
TFA	70 °C	THF-H ₂ O (4:1)	87%

solvent^[b]

results^[c]

^[a] amount of acid: HCl (2.0 equiv), AcOH (20 vol%), TFA (3.0 equiv)

^[b] 2.0 mL of total volume

^[c] isolated yield

Table S6. Screening of one-pot allylic reduction

OBoc	[(C ₃ H ₅)PdCl] ₂ (2.5 mol%) / PPh ₃ (15 mol%) THF-H ₂ O (4:1), rt, 12 h		BnO	
BnO	then, <i>cond</i>			
0.25 mmol				
acid ^[a]	temperature	reaction time	results ^[b]	
HCI / MeOH	50 °C	12 h	-	
AcOH	70 °C	12 h	-	
citric acid	70 °C	12 h	-	
tartaric acid	70 °C	12 h	-	
conc. HCI (aq.)	50 °C	12 h	65%	
conc. HCI (aq.)	50 °C	24 h	48%	
TFA	70 °C	12 h	69%	

^[a] amount of acid: HCl (2.0 equiv), AcOH (20 vol%), TFA (3.0 equiv), citric acid (5.0 equiv), tartaric acid (5.0 equiv) ^[b] isolated yield

Table S7. Leaving group screening of one-pot allylic reduction

_>	K
BnO	

[(C₃H₅)PdCl]₂ (2.5 mol%) / PPh₃ (15 mol%) THF-H₂O (4:1), rt, 12 h

BnO

0.25 mmol

then, TFA (3.0 equiv), 70 °C, 12 h				
Leaving group (X)	results ^[a]			
OAc	69%			
OCO ₂ Me	80%			

OBoc 69%

^[a] isolated yield

VI. Comparison with Other Allylic Reduction Methodology



Figure S1. Carbonates flanked by two π -systems

Doubly activated carbonates (Figure S1) are sensitive in that they are not suited for traditional reduction. For instance, carbonate **S1c** under conventional formate reduction conditions afforded deoxygenated alkene as a minor product with significant decomposition of starting material, while exposure to free-radical mediated conditions gave complex mixture with no trace of product.¹ Conventional reduction by formate or sodium borohydride gave regioisomeric alkenes even for simpler allylic carbonate **3b**. It is also noteworthy that allylic thiocarbonyl derivatives often suffer from the regioselectivity issue, significantly diminishing the utility of free-radical mediate reduction in allylic compounds.²

Scheme S1. Allylic Reduction of Bis-Allylic Carbonate



Reduction of *bis*-allylic carbonate (S2a) either with potassium sulfonylhydrazide (S2b) or with sulfinate (S2c) afforded the same skipped diene (S2i) through S_N2 -type reductive displacement. Palladium-catalyzed allylation of sulfonylhydrazone salt led to the regioisomeric mixtures in a 3:1 ratio (S2d:S2e)¹ while *S*-allylation with TBSOMS-Na (S2c) gave the single isomer S2f, demonstrating the enhanced selectivity of palladium catalysis with heteroatom nucleophile.

VII. Asymmetric Allylic Reduction

	o Me o (±)	CO ₂ Me	[(η ³ -allyl)PdCl] ₂ (2.5 r ligand (7.5 mol% TBSOMS-Na ⁿ Hex ₄ NBr solvent, rt, 1 h	nol%))) TBS		CO ₂ Me
ligand	TBSOMS-Na	ⁿ Hex ₄ NBr	solvent	yield (dr)	ee	note ^[a]
PPh ₃	1.1	-	THF-H ₂ O (4:1)	94% (1:2.37)	-	-
PPh_3	1.1	1.1	DCM-H ₂ O (3:1)	99% (1:1.37)	-	-
(<i>R</i> , <i>R</i>)	5.0	5.0	DCM-H ₂ O (3:1)	97% (10:1)	-	24 h
(S,S)	5.0	5.0	DCM-H ₂ O (3:1)	75% (10:1)	-	36 h
(<i>R</i> , <i>R</i>)	1.1	-	THF-H ₂ O (4:1)	94% (10:1)	-	-
(<i>R</i> , <i>R</i>)	1.1	1.1	DCM-H ₂ O (3:1)	99%	98%	-
(<i>R</i> , <i>R</i>)	1.1	0.25	DCM-H ₂ O (3:1)	99%	98%	2 h
(S,S)	1.1	0.25	DCM-H ₂ O (3:1)	99%	98%	2 h
(<i>R</i> , <i>R</i>)	1.1	0.25	DCM-H ₂ O (3:1)	91% (10:1)	-	2 h (1.5 mmol)
(S,S)	1.1	0.25	DCM-H ₂ O (3:1)	76% (10:1)	-	2 h (1.5 mmol)

Table S8. Asymmetric S-allylation of cyclic cis-carbonate

^[a] 0.1 mmol of carbonate in 2.0 mL of solvent unless specified.

The feasibility of asymmetric S-allylation of cyclic cis-carbonate using Trost's diamide ligands was probed (Table S8). It should be noted that a diastereomer possibly derived from palladium-coordination followed by reductive elimination, which has been proposed by Trost and others (J. Am. Chem. Soc. 1995, 117, 9662.), was observed as a byproduct. Formation of the byproduct also depends on the concentration, solvent, scale and degassing.

VIII. Compound Characterization

TBSO

sodium ((tert-butyldimethylsilyl)oxy)methanesulfinate (S1)

white solid; ¹H NMR (400 MHz, CD₃OD) δ 3.86 (s, 2H), 0.93 (s, 9H), 0.13 (s, 6H); ¹³C NMR (100 MHz, CD₃OD) δ 88.07, 26.35, 19.26, -4.92; IR (neat, v_{max}) 3860, 3635, 3331, 2798, 2513, 2226, 2044, 1668, 1419, 1114, 1010, 769 cm⁻¹; HRMS (ESI) *m/z* calc. for C₇H₁₇NaO₃SSi [M+H]⁺: 233.0638, found: 233.06392; HRMS (ESI) *m/z* calc. for C₇H₁₇NaO₃SSi [M+H]⁺: 255.0458, found: 255.04588; HRMS (ESI) *m/z* calc. for C₇H₁₇NaO₃SSi [M-Na]⁻: 209.0673, found: 209.06626.



(Z)-4-(benzyloxy)but-2-en-1-yl acetate (S2)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.41 – 7.27 (m, 5H), 5.82 (dt, *J* = 11.2, 6.3 Hz, 1H), 5.70 (dt, *J* = 11.2, 6.7 Hz, 1H), 4.62 (d, *J* = 6.7 Hz, 2H), 4.52 (s, 2H), 4.12 (d, *J* = 6.2 Hz, 2H), 2.05 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 170.93, 138.10, 130.97, 128.56, 127.94, 127.87, 126.77, 72.59, 65.78, 60.44, 21.05; IR (neat, *v*_{max}) 3332, 2958, 2835, 1701, 1410, 1097, 1040, 1024, 742, 679, 653 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₃H₁₆O₃ [M+Na]⁺: 243.0992, found: 243.0989.

BnO OCO₂Me

(Z)-4-(benzyloxy)but-2-en-1-yl methyl carbonate (S3)³

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.27 (m, 5H), 5.85 (dt, J = 11.4, 6.1 Hz, 1H), 5.73 (dt, J = 11.3, 6.6 Hz, 1H), 4.69 (d, J = 6.6 Hz, 2H), 4.50 (s, 2H), 4.13 (d, J = 6.1 Hz, 2H), 3.78 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.77, 138.05, 131.52, 128.56, 127.93, 127.87, 126.17, 72.59, 65.78, 63.75, 54.98; IR (neat, v_{max}) 2254, 1793, 1748, 1445, 1381, 1273, 1091, 912, 744, 650 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₃H₁₆O₄ [M+Na]⁺: 259.0941, found: 259.0940.

BnO₂ ОВос

(Z)-4-(benzyloxy)but-2-en-1-yl tert-butyl carbonate (S4)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.39 – 7.27 (m, 5H), 5.83 (dt, *J* = 12.2, 6.5 Hz, 1H), 5.74 (dt, *J* = 11.4, 6.5 Hz, 1H), 4.62 (d, *J* = 6.5 Hz, 2H), 4.51 (s, 2H), 4.13 (d, *J* = 6.0 Hz, 2H), 1.48 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 153.46, 138.10, 131.05, 128.55, 127.92, 127.84, 126.62, 82.37, 72.52, 65.78, 62.76, 27.89; IR (neat, *v*_{max}) 3414, 3275, 1913, 1856, 1780, 1685, 1568, 1423, 1299, 1080, 891, 767, 712 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₆H₂₂O₄ [M+Na]⁺: 301.1410, found: 301.1416.

BnO____OCO2Me

(E)-4-(benzyloxy)but-2-en-1-yl methyl carbonate (S5)⁴

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.27 (m, 5H), 5.91 (tdd, J = 15.6, 10.7, 5.1 Hz, 2H), 4.65 (d, J = 5.5 Hz, 2H), 4.52 (s, 2H), 4.05 (d, J = 4.8 Hz, 2H), 3.79 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.73, 138.19, 131.90, 128.56, 127.88, 127.83, 125.97, 72.53, 69.77, 67.82, 54.97; IR (neat, v_{max}) 3028, 2858, 2254, 1748, 1381, 1444, 1271, 1094, 913, 742, 651 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₃H₁₆O₄ [M+Na]⁺: 259.0941, found: 259.0940.

OBn OCO₂Me

(2E,4E)-6-(benzyloxy)hexa-2,4-dien-1-yl methyl carbonate (S6)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.27 (m, 5H), 6.31 (dt, *J* = 25.6, 10.6 Hz, 2H), 5.86 (dt, *J* = 14.3, 5.8 Hz, 1H), 5.77 (dt, *J* = 14.3, 5.8 Hz, 1H), 4.66 (d, *J* = 6.5 Hz, 2H), 4.52 (s, 2H), 4.07 (d, *J* = 6.0 Hz, 2H), 3.79 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.74, 138.28, 134.24, 131.77, 131.24, 128.55, 127.88, 127.80, 126.17, 72.36, 70.19, 68.10, 54.97; IR (neat, *v*_{max}) 2859, 2740, 1747, 1444, 1271, 1071, 993, 911, 740, 650 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₅H₁₈O₄ [M+Na]⁺: 285.1097, found: 285.1096.



(E)-6-(benzyloxy)hex-4-en-3-yl methyl carbonate (S7)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.27 (m, 5H), 5.88 (dt, J = 15.6, 5.4 Hz, 1H), 5.71 (dd, J = 15.6, 7.0 Hz, 1H), 5.03 (q, J = 6.7 Hz, 1H), 4.51 (s, 2H), 4.03 (d, J = 4.9 Hz, 2H), 3.77 (s, 3H), 1.70 (dtd, J = 27.8, 14.0, 6.9 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.42, 138.25, 130.37, 130.13, 128.55, 127.89, 127.80, 79.76, 72.39, 69.85, 54.77, 27.56, 9.57; IR (neat, v_{max}) 2972, 3029, 2855, 1747, 1442, 1267, 1075, 971, 949, 793, 740, 699 cm⁻¹; HRMS (ESI) m/z calc. for C₁₅H₂₀O₄ [M+Na]⁺: 287.1254, found: 287.1254.

OBn . CO₂Me

(E)-4-(benzyloxy)-1-phenylbut-2-en-1-yl methyl carbonate (S8)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.28 (m, 10H), 6.11 (d, *J* = 6.0 Hz, 1H), 5.97 (dd, *J* = 15.5, 6.0 Hz, 1H), 5.89 (dt, *J* = 15.6, 5.0 Hz, 1H), 4.50 (s, 2H), 4.04 (d, *J* = 5.0 Hz, 2H), 3.77 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.10, 138.57, 138.15, 130.37, 130.13, 128.75, 128.52, 127.87, 127.79, 127.12, 79.66, 72.50, 69.73, 54.95; IR (neat, *v*_{max}) 3390, 3342, 3306, 3091, 2860, 2735, 1056, 1000, 738 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₉H₂₀O₄ [M+Na]⁺: 335.1254, found: 335.1256.



(E)-6-(benzyloxy)-1-(trimethylsilyl)hex-4-en-1-yn-3-yl methyl carbonate (S9)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.28 (m, 5H), 6.12 (dt, *J* = 15.3, 5.2 Hz, 1H), 5.86 (dd, *J* = 15.3, 5.9 Hz, 1H), 5.77 (d, *J* = 6.1 Hz, 1H), 4.53 (s, 2H), 4.07 (d, *J* = 5.1 Hz, 2H), 3.81 (s, 3H), 0.18 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 154.84, 138.09, 132.62, 128.57, 127.92, 127.87, 126.46, 99.60, 93.42, 72.60, 69.35, 68.10, 55.18, -0.15; IR (neat, *v*_{max}) 3156, 3029, 2962, 2856, 2792, 2254, 1749, 1469, 1385, 1262, 1090, 989, 648 cm⁻¹;

HRMS (ESI) *m/z* calc. for C₁₈H₂₄O₄Si [M+Na]⁺: 355.1336, found: 355.1335.



(2E,5E)-1-(benzyloxy)hepta-2,5-dien-4-yl methyl carbonate (S10)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.29 (m, 5H), 6.28 (dt, J = 24.3, 10.6 Hz, 2H), 5.85 (dt, J = 13.9, 6.0 Hz, 1H), 5.68 (dd, J = 14.3, 7.0 Hz, 1H), 5.24 (m, 1H), 4.52 (s, 2H), 4.07 (d, J = 5.7 Hz, 2H), 3.77 (s, 3H), 1.38 (d, J = 6.5 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.21, 138.32, 131.93, 131.70, 131.46, 128.52, 127.86, 127.76, 74.95, 72.31, 70.23, 54.74, 20.42; IR (neat, v_{max}) 3688, 3535, 3159, 3031, 2855, 2793, 2257, 1740, 1603, 1444, 1058, 1000, 645 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₆H₂₀O₄ [M+Na]⁺: 299.1254, found: 299.1252.



(3E,5E)-7-(benzyloxy)-4-methyl-hepta-3,5-dien-2-yl methyl carbonate (S11)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.28 (m, 5H), 6.26 (d, J = 15.7 Hz, 1H), 5.85 (dt, J = 15.7, 6.0 Hz, 1H), 5.56 (dq, J = 12.7, 6.4 Hz, 1H), 5.45 (d, J = 8.9 Hz, 1H), 4.52 (s, 2H), 4.09 (d, J = 6.0 Hz, 2H), 3.75 (s, 3H), 1.86 (s, 3H), 1.36 (d, J = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.31, 138.38, 136.40, 136.10, 130.66, 128.54, 127.91, 127.77, 126.53, 72.36, 72.11, 70.79, 20.82, 13.03; IR (neat, v_{max}) 2954, 2852, 1741, 1441, 1330, 1258, 1149, 1113, 1070, 1034, 968, 940, 864, 791, 737, 698 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₇H₂₂O₄ [M+Na]⁺: 313.1410, found: 313.14114.



(Z)-4-(benzyloxy)-3-phenylbut-2-en-1-yl methyl carbonate (S12)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 7.36 (m, 10H), 6.06 (t, *J* = 6.8 Hz, 1H), 4.88 (d, *J* = 6.8 Hz, 2H), 4.52 (s, 2H), 4.46 (s, 2H), 3.80 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.82, 141.31, 140.28, 137.94, 128.55, 128.50,

128.05, 127.95, 127.92, 126.63, 125.77, 125.74, 72.44, 67.06, 64.53, 54.98; IR (neat, v_{max}) 3157, 3030, 2860, 2254, 1747, 146, 1381, 1271, 1091, 913, 746, 650 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₉H₂₀O₄ [M+Na]⁺: 335.1254, found: 335.1255.

OCO₂Me

3,3-diphenylallyl methyl carbonate (S13)

white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.38-7.15 (m, 10H), 6.19 (t, *J* = 7.0 Hz, 1H), 4.68 (d, *J* = 6.9 Hz, 2H), 3.76 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.86, 147.15, 141.47, 138.62, 129.82, 128.49, 128.36, 128.11, 128.02, 127.85, 121.71, 66.12, 54.97; IR (neat, *v*_{max}) 3413, 3400, 3377, 3012, 2858, 2809, 1444, 1267, 1058, 1005, 906, 733, 650 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₇H₁₆O₃ [M+Na]⁺: 291.0992, found: 291.0991.

DCO2Me

methyl ((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl) carbonate (S14)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 5.38 (t, J = 6.7 Hz, 1H), 5.09 (t, J = 5.8 Hz, 2H), 4.66 (d, J = 7.2 Hz, 2H), 3.77 (s, 3H), 2.08 (dt, J = 15.2, 7.4 Hz, 6H), 1.99 – 1.95 (m, 2H), 1.72 (s, 3H), 1.68 (s, 3H), 1.60 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 156.03, 143.42, 135.67, 131.49, 124.44, 123.69, 117.83, 64.88, 54.79, 39.83, 39.66, 26.86, 26.30, 25.85, 17.84, 16.68, 16.16; IR (neat, v_{max}) 3483, 3412, 3031, 2973, 2860, 2790, 1745, 1272, 1059, 1001, 908, 738, 651 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₇H₂₈O₃ [M+Na]⁺: 303.1931, found: 303.1929.



methyl (5-phenylpent-1-en-3-yl) carbonate (S15)⁵

white solid; ¹H NMR (400 MHz, CDCl₃) δ 7.30 - 7.26 (m, 2H), 7.21 - 7.19 (m, 3H), 5.83 (ddd, *J* = 17.2, 10.5, 6.7 Hz, 1H), 5.29 (dd, *J* = 31.7, 13.9 Hz, 2H), 5.09 (dd, *J* = 13.1, 6.6 Hz, 1H), 3.79 (s, 3H), 2.69 (dd, *J* = 15.3,

8.8 Hz, 2H), 2.05 (ddd, J = 13.8, 11.8, 6.9 Hz, 1H), 1.93 (ddt, J = 12.6, 9.8, 6.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 155.36, 141.25, 135.88, 128.61, 128.50, 126.19, 117.96, 78.69, 54.81, 36.01, 31.41. IR (neat, v_{max}) 3060, 2984, 2305, 1743, 1443, 1421, 1263, 939, 860, 735 cm⁻¹



(1RS,5SR)-5-(2-hydroxypropan-2-yl)-2-methylcyclohex-2-en-1-yl methyl carbonate (S16)

clear oil; ¹H NMR (400 MHz, CDCl₃) δ 5.73 (d, J = 5.4 Hz, 1H), 5.10 (s, 1H), 3.79 (s, 3H), 2.15 (t, J = 15.0 Hz, 2H), 1.85 – 1.77 (m, 2H), 1.73 (s, 3H), 1.49 (td, J = 13.5, 3.7 Hz, 1H), 1.20 (s, 3H), 1.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.95, 130.32, 128.57, 75.33, 72.13, 54.79, 39.30, 29.87, 27.82, 27.01, 26.55, 20.76; IR (neat, v_{max}) 3155, 2973, 2878, 2254, 1739, 1442, 1384, 1270, 1079, 1163, 980, 917, 745, 650 cm⁻¹ HRMS (ESI) m/z calc. for C₁₂H₂₀O₄ [M+Na]⁺: 251.1254, found: 251.1256.



(E)-(((4-(benzyloxy)but-2-en-1-yl)sulfonyl)methoxy)(tert-butyl)dimethylsilane (S17)

yellow oil (*E*:*Z* = 10:1); $R_f = 0.62$ (hexanes: EA = 2:1); ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.28 (m, 5H), 6.00 (dt, *J* = 15.5, 5.4 Hz, 1H), 5.82 (m, 1H), 4.52 (d, *J* = 5.0 Hz, 4H), 4.07 (d, *J* = 5.3 Hz, 2H), 3.74 (d, *J* = 7.4 Hz, 2H), 0.93 (s, 9H), 0.18 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 137.99, 137.12, 128.59, 127.91, 127.89, 118.53, 72.65, 69.70, 52.60, 25.69, 18.35, -5.21; IR (neat, *v*_{max}) 3543, 3252, 3088, 2858, 2743, 1794, 1470, 1049, 1012, 647 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₈H₃₀O₄SSi [M+Na]⁺: 393.1526, found: 393.1526

H H BnO

((but-3-en-1-yloxy)methyl)benzene (S18)¹

clear oil; $R_f = 0.68$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.27 (m, 5H), 5.84 (ddt, J = 17.0,

10.2, 6.7 Hz, 1H), 5.08 (ddd, *J* = 29.6, 14.2, 5.9 Hz, 2H), 4.52 (s, 2H), 3.53 (t, *J* = 6.8 Hz, 2H), 2.38 (q, *J* = 6.7 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 138.61, 135.41, 128.50, 127.79, 127.68, 116.50, 73.05, 69.76, 34.39.

BnO、 X

(((but-3-en-1-yl-2-d)oxy)methyl)benzene (S19)

clear oil; $R_f = 0.55$ (hexanes: EA = 10 :1); ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.27 (m, 5H), 5.85 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.06 (ddd, J = 14.5, 14.0, 4.7 Hz, 2H), 4.52 (s, 2H), 3.52 (d, J = 6.4 Hz, 2H), 2.37 (dt, J = 6.9, 3.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 138.59, 135.35, 128.49, 127.77, 127.67, 116.53, 73.04, 69.70, 34.37, 34.23, 34.03, 33.83; IR (neat, v_{max}) 3686, 3157, 3085, 2860, 2790, 2256, 1455, 1061, 999, 645 cm⁻¹; HRMS (ESI) m/z calc. for C₁₁H₁₃DO [M+Na]⁺: 186.1000, found: 186.0997.

BnO

(E)-((hexa-2,5-dien-1-yloxy)methyl)benzene (S20)¹

clear oil; $R_f = 0.59$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.28 (m, 5H), 5.85 (ddd, J = 16.8, 10.0, 5.1 Hz, 1H), 5.75 (m, 1H), 5.64 (dtd, J = 7.3, 5.9, 1.2 Hz, 1H), 5.04 (m, 2H), 4.51 (s, 2H), 4.00 (d, J = 5.9 Hz, 2H), 2.82 (t, J = 5.8 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 138.52, 136.47, 132.16, 128.51, 127.93, 127.70, 127.60, 115.70, 72.14, 70.87, 36.57.



(E)-((hex-3-en-1-yloxy)methyl)benzene (S21)^{1,6}

clear oil (*E*:*Z* = 3.3:1); R_f = 0.52 (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.28 (m, 5H), 5.55 (m, 1H), 5.41 (m, 1H), 4.52 (s, 2H), 3.48 (t, *J* = 6.6 Hz, 2H), 2.32 (dd, *J* = 13.6, 6.8 Hz, 2H), 2.03 (m, 2H), 0.97 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 138.73, 134.31, 128.49, 127.79, 127.64, 125.35, 72.98, 70.43, 33.20, 25.80, 13.93.



(E)-(4-(benzyloxy)but-2-en-1-yl)benzene (S22)^{1,7}

clear oil (*E*:*Z* = 7.2:1); R_f = 0.57 (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.15 (m, 10H), 5.88 (m, 1H), 5.67 (dt, *J* = 15.3, 6.1 Hz, 1H), 4.50 (s, 2H), 4.00 (d, *J* = 6.0 Hz, 2H), 3.40 (d, *J* = 6.5 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 140.13, 138.48, 133.18, 128.73, 128.56, 128.49, 127.92, 127.89, 127.69, 126.23, 72.17, 70.79, 38.69.



(E)-(6-(benzyloxy)hex-4-en-1-yn-1-yl)trimethylsilane (S23)¹

clear oil (E:Z = 8.1:1); R_f = 0.49 (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.28 (m, 5H), 5.88 (dt, J = 15.0, 5.9 Hz, 1H), 5.70 (ddd, J = 17.2, 11.1, 5.1 Hz, 1H), 4.52 (s, 2H), 4.03 (d, J = 5.1 Hz, 2H), 3.02 (d, J = 5.1 Hz, 2H), 0.17 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 138.42, 128.53, 128.38, 127.94, 127.76, 127.66, 103.66, 87.03, 72.27, 70.36, 23.07, 0.25.

QBn

((((2E,5E)-hepta-2,5-dien-1-yl)oxy)methyl)benzene (S24)¹

clear oil (*E*:*Z* = 2.5:1); R_f = 0.58 (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.27 (m, 5H), 5.72 (m, 1H), 5.62 (m, 1H), 5.55 - 5.40 (m, 2H), 4.50 (s, 2H), 3.98 (d, *J* = 6.0 Hz, 2H), 2.73 (m, 2H), 1.66 (d, *J* = 4.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 138.55, 133.22, 128.87, 128.47, 127.91, 127.65, 126.90, 126.32, 72.11, 70.94, 35.43, 18.03.



((((2E,5E)-4-methylhepta-2,5-dien-1-yl)oxy)methyl)benzene (S25)

clear oil (*E*:*Z* = 9.5:1); $R_f = 0.59$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.27 (m, 5H), 5.67 (dd, *J* = 15.5, 6.4 Hz, 1H), 5.56 (dt, *J* = 11.3, 5.9 Hz, 1H), 5.48 – 5.35 (m, 2H), 4.50 (s, 2H), 3.98 (d, *J* = 6.0 Hz, 2H), 2.83 (dd, *J* = 12.7, 6.5 Hz, 1H), 1.66 (d, *J* = 5.4 Hz, 3H), 1.08 (d, *J* = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 139.12, 138.57, 135.22, 128.50, 127.97, 127.68, 124.70, 123.98, 72.12, 71.09, 39.28, 20.32, 18.09. IR (neat, v_{max}) 3028, 2962, 2925, 2853, 1736, 1496, 1452, 1360, 1204, 1099, 1073, 1027, 968, 905, 735, 696 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₅H₂₀O [M+Na]⁺: 239.1406, found: 239.14064.

(1-(benzyloxy)but-3-en-2-yl)benzene (S26)⁸

clear oil; $R_f = 0.57$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.32 – 7.20 (m, 10H), 6.04 (ddd, J = 17.1, 10.4, 6.6 Hz, 1H), 5.12 (m, 2H), 4.51 (s, 2H), 3.68 (m, 3H); ¹³C NMR (101 MHz, cdcl₃) δ 141.58, 139.13, 138.46, 128.59, 128.46, 128.18, 127.72, 127.65, 126.72, 116.13, 73.74, 73.18, 49.90; IR (neat, v_{max}) 2961, 1660, 1511, 1473, 1429, 1347, 1141, 1036, 948, 777, 717, 697 cm⁻¹; HRMS (ESI) *m/z* calc. for C₁₇H₁₈O [M+Na]⁺: 261.1250, found: 261.1248.

prop-2-ene-1,1-diyldibenzene (S27)⁹

clear oil; $R_f = 0.18$ (hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.30 – 7.20 (m, 10H), 6.30 (m, 1H), 5.22 (d, J = 10.0 Hz, 1H), 4.99 (d, J = 17.0 Hz, 1H), 4.73 (d, J = 5.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 143.43, 140.78, 128.74, 128.54, 126.48, 116.49, 55.15.

(*E*)-3,7,11-trimethyldodeca-1,6,10-triene (S28)¹

clear oil; $R_f = 0.88$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 5.70 (ddd, J = 17.5, 10.3, 7.6 Hz, 1H), 5.10 (m, 2H), 4.98 – 4.90 (m, 2H), 2.16 – 1.95 (m, 7H), 1.68 (s, 3H), 1.60 (s, 3H), 1.59 (s, 3H), 1.32 (m, 2H), 0.99 (d, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 144.94, 135.02, 131.41, 124.71, 124.55, 112.59, 39.90, 37.47, 36.89, 26.86, 25.85, 25.77, 20.31, 17.84, 16.14.

Ph Ph

pent-4-en-1-ylbenzene (S29)¹

clear oil; $R_f = 0.85$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.30 – 7.25 (m, 2H), 7.20 – 7.18 (m, 3H), 5.84 (dddd, J = 16.9, 13.3, 6.6, 3.3 Hz, 1H), 5.03 (dd, J = 17.1, 1.6 Hz, 1H), 4.99 (m, 1H), 2.63 (t, J = 7.7 Hz, 2H), 2.10 (d, J = 7.4 Hz, 2H), 1.73 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 142.60, 138.75, 128.59, 128.41, 125.82, 114.84, 35.47, 33.44, 30.77.



2-(4-methylcyclohex-3-en-1-yl)propan-2-ol (S30)¹⁰

clear oil; R_f = 0.60 (hexanes: EA = 2:1); ¹H NMR (400 MHz, CDCl₃) δ 5.39 (s, 1H), 2.06 – 1.97 (m, 2H), 1.92 – 1.85 (m, 1H), 1.85 – 1.74 (m, 1H), 1.65 (s, 3H), 1.50 (tdd, *J* = 12.0, 4.9, 2.4 Hz, 1H), 1.32 – 1.23 (m, 2H), 1.19 (s, 3H), 1.18 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 134.15, 120.67, 72.89, 45.12, 31.14, 27.59, 27.02, 26.40, 24.10, 23.49.

(2S,3S)-2-methyl-3-phenyl-2-((Z)-prop-1-en-1-yl)oxirane (S31)

yellow oil; 98% ee¹¹; R_f = 0.12 (hexanes: EA = 50:1); ¹H NMR (400 MHz, CDCl₃) & 7.39 - 7.28 (m, 5H), 5.74

(dd, J = 11.0, 1.4 Hz, 1H), 5.61 (dq, J = 11.1, 6.9 Hz, 1H), 4.01 (s, 3H), 1.83 (dd, J = 6.9, 1.5 Hz, 3H), 1.17 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 136.28, 131.34, 128.26, 127.66, 126.99, 126.58, 64.98, 62.02, 17.44, 14.45; IR (neat, v_{max}) 3021, 2963, 1655, 1603, 1495, 1448, 1377, 1247, 1279, 1247, 1208, 1117, 1073, 1048, 1027, 991. 935, 899, 849, 816, 756, 697 cm⁻¹; [α]²⁰ _D = +27.3 (*c* 1.02, CHCl₃); HRMS (ESI) *m/z* calc. for C₁₂H₁₄O [M+Na]⁺: 197.0937, found: 197.09369.

(1R,4R,E)-4-((((tert-butyldimethylsilyl)oxy)methyl)sulfonyl)-2-methyl-1-phenylpent-2-en-1-ol (S32)

yellow oil; 97% *ee*; $R_f = 0.23$ (hexanes: EA = 3:1); ¹H NMR (400 MHz, CDCl₃) δ 7.35 – 7.28 (m, 5H), 5.73 (d, J = 10.5 Hz, 1H), 5.20 (d, J = 2.9 Hz, 1H), 4.54 (d, J = 11.6 Hz, 1H), 4.34 (d, J = 11.6 Hz, 1H), 4.16 (dq, J = 10.5, 7.0 Hz, 1H), 2.08 (d, J = 3.4 Hz, 1H), 1.51 (d, J = 7.0 Hz, 3H), 0.85 (s, 9H), 0.14 (s, 3H), 0.10 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 114.80, 141.48, 128.69, 128.01, 126.23, 119.46, 76.62, 75.55, 52.85, 25.63, 18.36, 12.97, 12.55, -5.09, -5.53; IR (neat, v_{max}) 3494, 2952, 2927, 2956, 1493, 1451, 1361, 1332, 1298, 1255, 1151, 1113, 1059, 1020, 937, 831, 782, 738, 701, 666 cm⁻¹; $[\alpha]^{20}_{D} = +11.8$ (*c* 0.91, CHCl₃); HRMS (ESI) *m/z* calc. for C₁₉H₃₂O₄SSi [M+Na]⁺: 407.1683, found: 407.16827. (CHIRALPACK IA, Hex:IPA = 98:2, 1.0 mL/min, t_R (minor) = 38.942 min, t_R (major) = 47.326 min)



(1*R*,2*S*,*E*)- 2-methyl-1-phenylpent-3-en-1-ol (S33)¹

yellow oil; 97% *ee*¹¹; $R_f = 0.21$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.23 (m, 5H), 5.48 (dt, *J* = 21.1, 6.0 Hz, 1H), 5.35 (dd, *J* = 15.4, 6.9 Hz, 1H), 4.58 (d, *J* = 4.7 Hz, 1H), 2.52 (dd, *J* = 12.6, 6.3 Hz, 1H), 1.98 (s, 1H), 1.65 (d, *J* = 6.0 Hz, 3H), 0.95 (d, *J* = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 142.79, 132.94, 128.08, 127.29, 126.63, 126.53, 77.50, 43.79, 18.24, 14.65; $[\alpha]^{20}_{D} = +0.92$ (*c* 0.89, CHCl₃); The absolute stereochemistry was determined by chiral HPLC analysis based on the previous report.¹² (CHIRALCEL OD-H, Hex:IPA = 99.8:0.2, 1.0 mL/min, t_R (major) = 57.693 min, t_R (minor) = 72.808 min)

(1*R*,2*S*,*E*)- 2-methyl-1-phenylpent-3-en-2-*d*-1-ol (834)

yellow oil; $R_f = 0.24$ (hexanes: EA = 10:1); ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.24 (m, 5H), 5.48 (m, 1H), 5.35 (d, J = 15.5 Hz, 1H), 2.00 (s, 1H), 1.65 (d, J = 6.1 Hz, 3H), 0.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 142.81, 132.90, 128.07, 127.28, 126.63, 126.51, 77.47, 43.54, 43.34, 43.15, 18.22, 14.58; IR (neat, v_{max}) 3395, 3027, 2962, 2918, 2852, 1603, 1493, 1451, 1375, 1249, 1198, 1084, 1054, 1022, 965, 910, 758, 700 cm⁻¹; $[\alpha]^{20}_{D}$ = +24.2 (*c* 0.98, CHCl₃); HRMS (ESI) *m/z* calc. for C₁₂H₁₅DO [M+Na]⁺: 200.1156, found: 200.11561.



Methyl (1RS,5RS)-5-((methoxycarbonyl)oxy)cyclohex-3-ene-1-carboxylate (S35)¹³

clear oil; R_f = 0.34 (hexanes: EA = 5:1); ¹H NMR (400 MHz, CDCl₃) δ 5.90 (dtd, *J* = 9.9, 3.7, 1.8 Hz, 1H), 5.73 – 5.69 (m, 1H), 5.28 – 5.24 (m, 1H), 3.79 (s, 3H), 3.70 (s, 3H), 2.73 (tdd, *J* = 10.7, 7.8, 3.0 Hz, 1H), 2.46 – 2.42 (m, 1H), 2.32 (ddd, *J* = 8.5, 5.9, 2.8 Hz, 2H), 1.84 (td, *J* = 12.3, 9.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 174.48, 155.47, 129.81, 126.19, 73.07, 54.80, 52.00, 37.73, 30.51, 27.25.



Methyl (1R,5R)-5-((((tert-butyldimethylsilyl)oxy)methyl)sulfonyl)cyclohex-3-ene-1-carboxylate (36a)

clear oil; 98% ee^{11} ; R_f = 0.24 (hexanes: EA = 5:1); ¹H NMR (400 MHz, CDCl₃) δ 6.16 – 6.12 (m, 1H), 5.88 (d, *J* = 10.1 Hz, 1H), 4.68 (d, *J* = 11.9 Hz, 1H), 4.56 (d, *J* = 11.9 Hz, 1H), 3.97 (m, 1H), 3.72 (s, 3H), 2.83 – 2.59 (m, 1H), 2.53 – 2.49 (m, 1H), 2.44 – 2.39 (m, 1H), 2.34 – 2.29 (m, 1H), 2.10 (dd, *J* = 24.6, 12.8 Hz, 1H), 0.92 (s, 9H), 0.19 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 174.36, 132.94, 118.13, 76.70, 57.88, 52.20, 38.42, 27.43, 25.67, 24.85, 18.33, -5.18, -5.31; IR (neat, *v*_{max}) 2953, 2931, 2857, 1733, 1463, 1436, 1363, 1302, 1255, 1209, 1150, 1112, 1058, 1005, 939, 917, 886, 831, 783, 732 cm⁻¹; [α]²⁰ _D = +24.6 (*c* 0.26, CH₃OH); HRMS (ESI) *m/z*

calc. for C₁₅H₂₈O₅SSi [M+Na]⁺: 371.1319, found: 371.1322.

Methyl (15,55)-5-((((tert-butyldimethylsilyl)oxy)methyl)sulfonyl)cyclohex-3-ene-1-carboxylate (36b)

clear oil; 98% ee^{11} ; R_f = 0.24 (hexanes: EA = 5:1); ¹H NMR (400 MHz, CDCl₃) δ 6.16 – 6.12 (m, 1H), 5.88 (d, *J* = 10.1 Hz, 1H), 4.68 (d, *J* = 11.9 Hz, 1H), 4.56 (d, *J* = 11.9 Hz, 1H), 3.97 (m, 1H), 3.72 (s, 3H), 2.83 – 2.59 (m, 1H), 2.53 – 2.49 (m, 1H), 2.44 – 2.39 (m, 1H), 2.34 – 2.29 (m, 1H), 2.10 (dd, *J* = 24.6, 12.8 Hz, 1H), 0.92 (s, 9H), 0.19 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 174.36, 132.94, 118.13, 76.70, 57.88, 52.20, 38.42, 27.43, 25.67, 24.85, 18.33, -5.18, -5.31; IR (neat, v_{max}) 2953, 2931, 2857, 1733, 1463, 1436, 1363, 1302, 1255, 1209, 1150, 1112, 1058, 1005, 939, 917, 886, 831, 783, 732 cm⁻¹; $[\alpha]^{20}_{D}$ = -13.7 (*c* 0.25, CH₃OH); HRMS (ESI) *m/z* calc. for C₁₅H₂₈O₅SSi [M+Na]⁺: 371.1319, found: 371.1322.



Methyl (R)-cyclohex-3-ene-1-carboxylate (S37a)¹

yellow oil; 96% ee^{11} ; R_f = 0.29 (hexanes: EA = 20:1); ¹H NMR (400 MHz, CDCl₃) δ 5.71 – 5.66 (m, 2H), 3.69 (s, 3H), 2.60 – 2.54 (m, 1H), 2.26 – 2.24 (m, 2H), 2.12 – 2.08 (m, 2H), 2.01 (ddd, J = 12.4, 9.8, 6.3 Hz, 1H), 1.69 (dddd, J = 12.8, 11.3, 9.5, 6.5 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 176.35, 126.72, 125.26, 51.67, 39.31, 27.53, 25,17, 24.52.

CO₂Me

Methyl (S)-cyclohex-3-ene-1-carboxylate (S37b)¹⁴

yellow oil; 96% ee^{11} ; R_f = 0.29 (hexanes: EA = 20:1); ¹H NMR (400 MHz, CDCl₃) δ 5.71 – 5.66 (m, 2H), 3.69 (s, 3H), 2.60 – 2.54 (m, 1H), 2.26 – 2.24 (m, 2H), 2.12 – 2.08 (m, 2H), 2.01 (ddd, *J* = 12.4, 9.8, 6.3 Hz, 1H),

1.69 (dddd, J = 12.8, 11.3, 9.5, 6.5 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 176.35, 126.72, 125.26, 51.67, 39.31, 27.53, 25,17, 24.52.

VIII. References

- (1) Movassaghi, M.; Ahmad, O.K. Angew. Chem. Int. Ed. 2008, 47, 8909.
- (2) Maity, S.; Ghosh, S. Tetrahedron Lett. 2007, 48, 3355.
- (3) Wuts, P. G. M.; Ashford, S. W.; Anderson, A. M.; Atkins, J. R. Org. Lett. 2003, 5, 1483.
- (4) Tosatti, P.; Horn, J.; Campbell, A. J.; House, D.; Nelson, A.; Marsden, S. P. Adv. Synth. Catal. 2010, 352, 3153.
- (5) Li, C.; Breit, B. Chem. Eur. J. 2016, 22, 14655.
- (6) Alonso, F.; Osante, I.; Yus, M. Tetrahedron 2007, 63, 93.
- (7) Tang, X.-L.; Wu, Z.; Li, M.-B.; Gu, Y.; Tian, S.-K. Eur. J. Org. Chem. 2012, 4107.
- (8) Lonca, G. H.; Ong, D. Y.; Tran, T. M.; Tejo, C.; Chiba, S.; Gagosz, F. Angew. Chem. Int. Ed. 2017, 56, 11440.
- (9) Hussain, N.; Frensch, G.; Zhang, J.; Walsh, P. J. Angew. Chem. Int. Ed. 2014, 53, 3693.
- (10) da Silva, M. J.; Carari, D. M.; da Silva, A. M. RSC Adv. 2015, 5, 10529.
- (11) Enantiomeric excess was determined by using Eu(hfc)₃ as a chiral shift reagent (S31, S33, S36, S37).
- (12) Althaus, M.; Mahmood, A.; Suárez, J. R.; Thomas, S. P.; Aggarwal, V. K. J. Am. Chem. Soc. 2010, 132, 4025.
- (13) Misale, A.; Niyomchon, S.; Luparia, M.; Maulide, N. Angew. Chem. Int. Ed. 2014, 53, 7068.
- (14) Kashima, C.; Fukusaka, K.; Takahashi, K.; Yokoyama, Y. J. Org. Chem. 1999, 64, 1108.

















































































S50









Chiral HPLC Analysis



CHIRALPACK IA | Hex:IPA = 98:2 | Flow rate: 1.0 mL/min



Signal 5: DAD1 E, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	37.353	BB	1.3755	1.02431e5	997.92517	50.5523
2	45.384	BB	2.5391	1.00193e5	492.16513	49.4477



Signal 5: DAD1 E, Sig=220,8 Ref=360,100

Peak #	RetTime [min]	Туре	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	38.942	MM	0.8244	348.07510	7.03685	1.6680
2	47.326	MM	2.8162	2.05198e4	121.43780	98.3320











